Results 1 to 10 of about 383,796 (264)

Plasma circRNAs as Biomarkers in Cancer

Cancer Management and Research, 2021
The incidence and mortality of cancer are increasing each year. At present, the sensitivity and specificity of the blood biomarkers that were used in clinical practice are low, which make the detection rate of cancer decrease. With advances in bioinformatics and technology, some non-coding RNA as biomarkers can be easily detected through some ...
Qⅰan Zhou, Lin-Ling Ju
exaly   +7 more sources

Plasma Biomarkers in Diverse Populations [PDF]

Alzheimers Dement
Abstract Background Recent advancements in plasma biomarkers, particularly p ‐tau217, have highlighted its potential for early Alzheimer's Disease (AD) detection.
Loewenstein D.
europepmc   +3 more sources

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals

Frontiers in Aging Neuroscience, 2022
BackgroundPlasma-derived β-amyloid, tau, and neurodegeneration (ATN) biomarkers can accurately diagnose Alzheimer’s disease (AD) and predict its progression.
Qingling Sun, Jingnian Ni, Mingqing Wei, Siwei Long, Ting Li, Dongsheng Fan, Tao Lu, Jing Shi, Jinzhou Tian   +8 more
doaj   +1 more source

Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease

Frontiers in Aging Neuroscience, 2023
BackgroundSeveral blood-based biomarkers are promising to be used in the diagnosis of Alzheimer’s disease (AD) including Aβ42/40, p-tau181, and neurofilament light (NfL). The kidney is associated with the clearance of proteins.
Bin Zhang, Cheng Zhang, YuYe Wang, LeiAn Chen, YaNan Qiao, Yu Wang, DanTao Peng, for the Alzheimer’s Disease Neuroimaging Initiative   +7 more
doaj   +1 more source

Diagnostic Blood Biomarkers in Alzheimer’s Disease

Biomedicines, 2022
Potential biomarkers for Alzheimer’s disease (AD) include amyloid β1–42 (Aβ1–42), t-Tau, p-Tau181, neurofilament light chain (NFL), and neuroimaging biomarkers. Their combined use is useful for diagnosing and monitoring the progress of AD.
Jung Eun Park, Tamil Iniyan Gunasekaran, Yeong Hee Cho, Seong-Min Choi, Min-Kyung Song, Soo Hyun Cho, Jahae Kim, Ho-Chun Song, Kyu Yeong Choi, Jang Jae Lee, Zee-Yong Park, Woo Keun Song, Han-Seong Jeong, Kun Ho Lee, Jung Sup Lee, Byeong C. Kim   +15 more
doaj   +1 more source

Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity

Frontiers in Immunology, 2023
BackgroundDysregulated immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are thought to underlie the progression of coronavirus disease 2019 (COVID-19) to severe disease.
Rachel MacCann, Rachel MacCann, Rachel MacCann, Alejandro Abner Garcia Leon, Gabriel Gonzalez, Gabriel Gonzalez, Gabriel Gonzalez, Michael J. Carr, Michael J. Carr, Michael J. Carr, Eoin R. Feeney, Eoin R. Feeney, Obada Yousif, Aoife G. Cotter, Aoife G. Cotter, Eoghan de Barra, Eoghan de Barra, Corinna Sadlier, Peter Doran, Patrick W. Mallon, Patrick W. Mallon, Patrick W. Mallon   +21 more
doaj   +1 more source

Plasma biomarkers of mouse aging [PDF]

AGE, 2010
Normal aging is accompanied by a series of physiological changes such as gray hair, cataracts, reduced immunity, and increased susceptibility to disease. To identify novel biomarkers of normal aging, we analyzed plasma proteins of male mice longitudinally from 2 to 19 months of age.
Juan, Ding, John J, Kopchick
openaire   +2 more sources

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Liver Cancer, 2021
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa   +14 more
doaj   +1 more source

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
Introduction Objectively‐defined subtle cognitive decline (Obj‐SCD) and plasma phosphorylated‐tau181 (p‐tau181) are promising early Alzheimer's disease (AD) markers.
Kelsey R. Thomas, Katherine J. Bangen, Emily C. Edmonds, Alexandra J. Weigand, Kayla S. Walker, Mark W. Bondi, Douglas R. Galasko, for the Alzheimer's Disease Neuroimaging Initiative   +7 more
doaj   +1 more source

Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China

Frontiers in Aging Neuroscience, 2021
Background: Alzheimer's disease (AD) is the most common type of dementia and has no effective treatment to date. It is essential to develop a minimally invasive blood-based biomarker as a tool for screening the general population, but the efficacy ...
Bin Jiao, Bin Jiao, Bin Jiao, Hui Liu, Lina Guo, Xinxin Liao, Xinxin Liao, Xinxin Liao, Yafang Zhou, Yafang Zhou, Yafang Zhou, Ling Weng, Ling Weng, Ling Weng, Xuewen Xiao, Lu Zhou, Xin Wang, Yaling Jiang, Qijie Yang, Yuan Zhu, Lin Zhou, Lin Zhou, Lin Zhou, Weiwei Zhang, Junling Wang, Junling Wang, Junling Wang, Xinxiang Yan, Xinxiang Yan, Xinxiang Yan, Beisha Tang, Beisha Tang, Beisha Tang, Lu Shen, Lu Shen, Lu Shen, Lu Shen, Lu Shen, Lu Shen   +38 more
doaj   +1 more source